Sarepta Therapeutics was awarded a voucher for a fast-track drug review by the Food and Drug Administration when the company's medicine for Duchenne muscular dystropy was approved Sept. 19. Now Sarepta is looking to sell the voucher to the highest bidder.
Mick Wiggins/Ikon Images/Getty Images
Duchenne muscular dystrophy patients Jack Willis (center), Nolan Willis (right) and Max LeClaire, attended the opening of Sarepta Therapeutics new headquarters in Cambridge, Mass., in 2014.
Boston Globe via Getty Images
In 2015, the Sandoz unit of drugmaker Novartis won Food and Drug Administration approval of a drug called Zarxio, which is similar to Amgen's Neupogen, a medicine that boosts the production of white blood cells.
Sebastien Bozon/AFP/Getty Images
Bottles of the abortion-inducing drug RU-486, which is used to medically induce abortions in a two-step process. Women take mifepristone (left), and days later, they take misoprostol.